Mitiglinide for type 2 diabetes treatment (Q38132853)

29 August 2017

Mitiglinide for type 2 diabetes treatment (English)

1 reference

29 August 2017

1 reference

Haley M Phillippe

1

1 reference

PubMed ID

23992284

29 August 2017

Kurt A Wargo

series ordinal

2

1 reference

PubMed ID

23992284

29 August 2017

language of work or name

English

0 references

publication date

30 August 2013

1 reference

Expert Opinion on Pharmacotherapy

29 August 2017

1 reference

29 August 2017

14

1 reference

29 August 2017

15

1 reference

29 August 2017

2133-2144

1 reference

Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial

29 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.834048

Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.834048

The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.834048

Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.834048

Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.834048

Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.834048

Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.834048

Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.834048

Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.834048

Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.834048

Pleiotropic effects of mitiglinide in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.834048

Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.834048

Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.834048

Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.834048

Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.834048

Treatment with glimepiride, but not mitiglinide and short-acting insulin, resists body weight and abdominal fat reduction under dietary energy restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.834048

10.1517/14656566.2013.834048

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23992284